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Elevated cardiac troponin T contributes to
prediction of worse in-hospital outcomes after
endovascular therapy for acute limb ischemia
Birgit Linnemann, MD,a,b Thilo Sutter,a Sebastian Sixt, MD,a Aljoscha Rastan, MD,a
Uwe Schwarzwaelder, MD,a Elias Noory, MD,a Karlheinz Buergelin, MD,a Ulrich Beschorner, MD,a and
Thomas Zeller, MD,a Bad Krozingen and Frankfurt/Main, Germany
Introduction: The present study evaluated whether elevated cardiac troponin T (cTnT) was predictive of an increased risk
for death or amputation in patients with acute lower limb ischemia (ALI). ALI is one of the most frequent causes of
amputation, with mortality rates for ALI ranging from 15% to 20%.
Methods:This study included 254 consecutive ALI patients (155men, 99women; mean age, 71.6 13.2 years) presenting
with Rutherford categories I, IIA, or IIB according to the classification for ALI.
Results: ALI was caused by thromboembolism (29.5%), local arterial thrombosis (53.1%), or bypass graft occlusion
(16.9%). Restoration of arterial blood flow was obtained by an endovascular approach, with a primary success rate of
98.4%. Rates were low for in-hospital mortality (3.9%) and amputation (5.1%). Patients who died or required amputation
more frequently presented with elevated cTnT >0.01 ng/mL (52.2% vs 25.5%, P  .01) and impaired renal function
(chronic kidney disease stage 3-5; 60.9% vs 38.1%; P  .04). After controlling for age, sex, C-reactive protein, renal
function, presence or absence of coronary artery disease, and traditional vascular risk factors, as well as the interval
between symptom onset and revascularization, the relationship between cTnT and a worse in-hospital outcome remained
significant (hazard ratio, 3.4; 95% confidence interval, 1.3-8.5; P  .010).
Conclusions: ALI patients frequently have elevated cTnT, which is associated with increased in-hospital mortality and
amputation. Even small cTnT elevations predict a markedly increased risk of worse in-hospital outcome; however, the
overall mortality and amputation rate in our study was low. (J Vasc Surg 2012;55:721-9.)
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tThe cardiac troponins are established markers of myo-
cardial injury and necrosis. In the clinical setting of myo-
cardial ischemia, evidence of increased cardiac troponins
has been defined as the cornerstone of the redefinition of
myocardial infarction.1 Cardiac troponins are also elevated
in patients with varying degrees of chronic kidney disease
(CKD).2 Among patients with end-stage renal disease
(ESRD), elevated cardiac troponin T (cTnT) was found in
17% to 43% of patients, whereas elevated cardiac troponin I
(cTnI) was found in 12% to 18% of patients.3,4 However,
there is evidence that this finding cannot be exclusively
related to an accumulation due to renal failure. The increase
in cardiac troponins is not correlated with creatinine con-
centration,5 and elimination of cTnI was independent of
renal function.6 Furthermore, cTnT levels remain elevated
even after successful renal transplantation.7 In their meta-
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doi:10.1016/j.jvs.2011.10.024nalysis of 28 studies, including 3931 patients with ESRD,
han et al8 suggested that increased levels of cTnT and
TnI are independent predictors of death.
Recently, some investigations have reported that ele-
ated cardiac troponins may also be of prognostic value in
atients with peripheral arterial occlusive disease (PAOD)
ith acute or chronic critical limb ischemia.9-11 However,
any PAOD patients have impaired renal function, and
ardiac troponins often increase with declining glomerular
ltration rate (GFR). Moreover, CKD itself is associated
ith increased cardiovascular death.12,13 This study was
erformed to test the hypothesis that TnT is an indepen-
ent risk indicator of a worse in-hospital outcome (ie, death
r amputation), in PAOD patients with acute lower limb
schemia (ALI) of Rutherford categories I, IIA, and IIB.
ETHODS
Study design. In a retrospective study design, we
nalyzed data of 260 consecutive ALI patients (161 men,
9 women) treated between January 2007 and Decem-
er 2009. The protocol was approved by the local ethics
ommittee and registered at http://ClinicalTrials.Gov
NCT01087385). The study cohort had an average age of
1.5 years (range, 20-98 years). ALI was defined as sudden
nset or acute deterioration of clinical symptoms of lower
imb ischemia (ie, severe claudication or rest pain) within
he last 14 days. All patients included in this study were in
he Rutherford clinical categories I, IIA, or IIB for ALI14
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arterial blood flow.
Laboratory assessment. Blood samples were drawn at
hospital admission. Cardiac TnT was measured using the
fourth-generation assay Elecsys Troponin T on Cobas
6000 e601 systems (Roche Diagnostics, Mannheim, Ger-
many), according to the manufacturer’s recommendations.
The 99th percentile value for the reference population used
by the manufacturer of the assay was 0.01 ng/mL, and the
lowest level at which the coefficient of variation was 10%
was 0.03 ng/mL.15 Two different cutoff criteria were used
to define elevated cTnT: 0.01 ng/mL, which corresponds
to the 99th percentile of a reference population and the
lowest level of detection, and 0.03 ng/mL, which repre-
sents the cutoff value for the definition of myocardial
necrosis with this assay using the 10% total imprecision
coefficient of variation criteria.16
Laboratory testing also included automated and stan-
dardized testing of complete blood cell counts and serum
levels of creatinine, C-reactive protein (CRP), fibrinogen,
creatine kinase (CK), CK-MB, lactate dehydrogenase, and
myoglobin. Blood sampling was repeated at least twice
daily to assess maximum values of CK (CKmax) and myo-
globin (myoglobinmax) during the hospital stay. The esti-
mated GFR (eGFR) was determined by the Cockgroft-
Gault formula and classified using the standards of the
National Disease Outcomes Quality Initiative.17 We de-
fined CKD as an eGFR 60 mL/min.
Clinical evaluation and electrocardiograph registra-
tion. Six patients sustained an acute coronary syndrome
(ACS)14 days before the onset of ALI and were censored
from further statistical analysis. There was no clinical evi-
dence of myocardial ischemia among the remaining 254 pa-
tients. We analyzed patients’ electrocardiograms (ECGs),
which were performed simultaneously with blood sampling
at the time of admission to the hospital. According to the
consensus document of the Joint European Society of
Cardiology (ESC)/American College of Cardiology Foun-
dation (ACCF)/American Heart Association (AHA)/
World Heart Federation (WHF) Task Force for the Redef-
inition of Myocardial Infarction,1 we registered ECG
changes that may be indicative of acute myocardial isch-
emia:
1. ST elevation at the J-point in two contiguous leads with
the cutoff points of 0.2 mV in men or 0.15 mV in
women in leads V2-V3 and/or0.1 mV in other leads;
2. horizontal or down-sloping ST depression of0.05mV
or T inversion of 0.1 mV in two contiguous leads, or
both; and
3. the presence of left bundle branch block.
Patient outcomes. Differences in in-hospital outcome
were determined for patients with elevated and normal
cTnT concentrations. The primary end point was the rate
of in-hospital death or amputation. Causes of death were
determined from death certificates or medical reports.
Statistical analysis. Statistical analysis was performed
using SPSS 17.0 software (SPSS, Chicago, Ill). In addition do obtaining descriptive statistics with the mean standard
eviation (SD) or median and range, we performed the 2
est in cross-tabulations and the Mann-Whitney U test for
omparison of metric variables. Differences in in-hospital
utcome were compared between patients with elevated
nd normal cTnT concentrations. Unadjusted and adjusted
azard ratios (HRs) of the combined end point of death or
mputation, and 95% confidence intervals (CIs) were esti-
ated using Cox proportional hazard models. All adjusted
odels were fit with age, sex, coronary artery disease
CAD), established vascular risk factors, eGFR, and other
ariables differing in univariate analyses between the two
roups. All tests were two-sided, and the criterion for
tatistical significance was P  .05.
ESULTS
Study cohort. Clinical characteristics and demographic
nformation available for the study cohort of 254 ALI
atients (61% men) are summarized in Table I. Mean
atient age was 71.6  13.2 years. Patients presented with
linical symptoms according to Rutherford categories I
36%), IIA (30%), and IIB (34%) for ALI. The localization
r proximal extension of the arterial occlusion most often
nvolved the femoral arteries (62.6%), followed by the
opliteal artery (22.4%), iliac arteries (11.0%), and tibial or
eroneal arteries (3.9%). Arterial occlusion was caused by
rterial thromboembolism in 29.5% and by a local throm-
otic process in 53.1%. Most of these involved normal-
ized vessels with pre-existing atherosclerotic lesions, and
n arterial aneurysm was detected as the cause of arterial
cclusion in nine cases (6.7%). Bypass graft occlusions
ontributed to 16.9% of ALI cases. In only one patient
ould the cause of the arterial occlusion not be determin-
d. Catheter-guided revascularization techniques included
echanical thrombectomy (61.8%), catheter thrombus as-
iration (31.9%), local thrombolysis (53.1%), angioplasty
nd stent placement (76.0%), and atherectomy (2.0%).
Patient in-hospital outcomes. All patients under-
ent interventional recanalization procedures to restore
rterial blood flow to the lower extremity, with an overall
rimary success rate of 98.4%. The mean time between the
nset of symptoms and revascularization was 2.8  2.6
ays. The revascularization procedure was performed 24
ours after the onset of symptoms in 119 patients (46.5%)
nd 72 hours in 195 (76.8%). In four patients (1.6%),
ndovascular revascularization was not successful. Of these,
wo patients underwent emergency femoropopliteal bypass
urgery on the same day, one patient underwent major
mputation within the next few days, and one patient died
n the course of the hospital stay.
The median duration of the hospital stay was 7.1 days
range, 1-57 days). Overall rates were 10 of 254 (3.9%) for
n-hospital mortality and 13 of 254 (5.1%) for amputation,
hich were low. Major amputation was unavoidable in
even patients (2.7%), and six patients (2.4%) underwent
inor amputation. Death was caused by progressive gan-
rene, septicemia, or systemic inflammatory response syn-
rome (SIRS), followed by multiorgan failure in eight
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Volume 55, Number 3 Linnemann et al 723patients, hemorrhagic shock due to gastrointestinal bleed-
ing after local thrombolysis in one patient, and aortic valve
endocarditis with thromboembolic complications in an-
other patient. No patients sustained a fatal myocardial
infarction. Clinical characteristics available for the 23 pa-
tients who died or underwent amputation during the hos-
pital stay and the 231 patients with amputation-free sur-
vival are summarized in Table I.
Elevated cTnT and in-hospital outcome. Patients
with worse in-hospital outcome (ie, death or amputation)
differed from those with amputation-free survival with re-
gard to cTnT, CK, CK-MB, CK , lactate dehydrogenase,
Table I. Clinical characteristics and demographics of the 2
Characteristicsa
Total cohort
(n  254)
In-
Age, years 72  13
Male sex 155 (61)
Vascular risk factors and comorbidities
Current smoker 64 (25)
Diabetes mellitus 75 (30)
Arterial hypertension 213 (84)
Hypercholesterolemia 175 (69)
Coronary artery disease 91 (36)
Atrial fibrillation 78 (31)
Prior cerebral infarction 25 (10)
Prior peripheral revascularization
Endovascular 118 (47)
Bypass surgery 57 (22)
Prior amputation 20 (8)
Chronic kidney disease stages 3-5 102 (40)
End-stage renal disease 9 (4)
PAOD characteristics
Rutherford category
I 90 (36)
IIA 77 (30)
IIB 87 (34)
Ankle-brachial index 0.19  0.32
Causes of acute limb ischemia
Thromboembolism 75 (30)
Local thrombosis 135 (53)
Bypass graft occlusion 43 (17)
Unknown 1 (0.4)
Proximal extension of arterial occlusion
Iliac arteries 19 (7)
Femoral arteries 161 (63)
Popliteal artery 63 (2)
Tibial or peroneal arteries 11 (4)
Endovascular revascularization
Mechanical thrombectomy 155 (61)
Local thrombolysis 135 (53)
Catheter thrombus aspiration 81 (32)
Angioplasty/stenting 193 (76)
Mechanical atherectomy 5 (2)
Comedication on admission
Antiplatelet therapy 230 (91)
Vitamin K antagonist 61 (24)
Lipid-lowering drug 173 (68)
-blocker 156 (61)
ACE inhibitor/AT1RA 188 (74)
ACE, Angiotensin converting enzyme; AT1RA, angiotensin type 1 recepto
aCategoric data are presented as number (%) and continuous data as mean 
bP values related to the comparison of in-hospital death or amputation vs ammax
and myoglobinmax (Table II). Levels for cTnT of 0.01 Und 0.03 ng/mL were found in 52.2% and 34.8% of
atients with worse in-hospital outcomes (P  .01), respec-
ively, whereas 25.5% and 12.6% of patients with amputation-
ree survival had cTnT elevation (P .009, respectively).
An elevated cTnT of 0.01 ng/mL was present in 71
LI patients (28.0%) at admission to the hospital; and in 37
14.6%), the cTnT levels were even 0.03 ng/mL. The
umulative rates for in-hospital death or amputation were
6.9% for patients with elevated cTnT (0.01 ng/mL) vs
.0% for those with normal cTnT (P  .01). Correspond-
ng results were found for patients with cTnT levels of
0.03 ng/mL (21.5%) vs0.03 ng/mL (6.9%, P .009).
tudy patients at baseline
al death or amputation
(n  23)
Amputation-free survival
(n  231) Pb
77  11 71  13 .042
13 (57) 142 (62) .659
3 (13) 61 (26) .211
7 (30) 68 (30) .99
16 (70) 197 (85) .070
9 (39) 166 (72) .003
7 (30) 84 (36) .654
8 (36) 70 (30) .630
2 (9) 23 (10) .846
8 (35) 110 (48) .278
5 (22) 52 (23) .932
1 (4) 19 (8) .556
14 (61) 88 (38) .044
2 (9) 7 (3) .191
1 (4) 89 (39) .001
1 (4) 76 (33) .003
21 (91) 66 (29) .001
0.08  0.03 0.20  0.33 .020
8 (35) 67 (29) .358
10 (44) 125 (54) .384
4 (17) 39 (17) .870
0 1 .99
2 (9) 17 (7) .685
15 (65) 146 (63) .849
5 (22) 58 (25) .721
1 (4) 10 (4) .997
13 (57) 142 (62) .642
13 (57) 122 (53) .828
17 (74) 156 (68) .643
19 (83) 174 (75) .610
0 (0) 5 (2) .476
12 (52) 210 (91) .001
2 (9) 59 (26) .078
16 (69) 157 (68) .875
17 (74) 139 (60) .262
20 (87) 168 (73) .217
gonist; PAOD, peripheral arterial occlusive disease.
dard deviation.
tion-free survival.54 s
hospit
r antanadjusted HRs were 2.8 (95% CI, 1.2-6.8) for cTnT
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March 2012724 Linnemann et alvalues of 0.01 ng/mL and 3.2 (95% CI, 1.3-7.9) for
cTnT values of 0.03 ng/mL.
Elevated cTnT and comorbidities. When compared
with patients with cTnT values 0.01 ng/mL, patients
with higher cTnT levels more frequently presented with
diabetes, CAD, atrial fibrillation, a history of cerebral in-
farction, and impaired renal function (Table III). An ele-
vated cTnT was also associated with higher levels of skeletal
muscle enzymes (ie, CK, myoglobin, lactate dehydroge-
nase). Apart from local thrombolysis, which was less fre-
quently performed in patients with elevated cTnT values
(39.4% vs 58.5%, P  .008), there was no difference in
revascularization procedures performed between the
groups (Table IV) or the interval between symptom onset
and revascularization (2.9 vs 2.5 days, P  .158). We
observed a higher rate of in-hospital mortality among pa-
tients with cTnT values 0.01 ng/mL compared with
patients with normal cTnT values (11.3% vs 1.1%; P 
.001). No significant difference for cTnT levels was ob-
served in the amputation rate, but the case number was too
small to draw definitive conclusions.
Elevated cTnT and renal function. Impaired renal
function was more frequently observed in patients with
worse in-hospital outcomes, as represented by higher
levels of serum creatinine (1.6  1.1 vs 1.2  1.0
Table II. Laboratory parameters in patients with acute low
amputation vs amputation-free survival)
Variablea
In-hospital death or am
(n  23)
Cardiac troponin T
0.01 ng/mL 12 (52.2)
0.03 ng/mL 8 (34.8)
Skeletal muscle enzymes
CK, U/mL 973  1143
CK-MB, U/mL 36.6  23.4
LDH, U/mL 308  116
CKmax, U/mL 3893  4846
Myoglobinmax, ng/mL 8388  10,81
CKD
Creatinine, mg/dL 1.6  1.1
eGFR, mL/min 55  33
CKD stage, eGFR
1, 90 mL/min 5 (21.7)
2, 60-89 mL/min 4 (17.4)
3, 60 mL/min 9 (39.1)
4, 15-29 mL/min 3 (13.0)
5, 15 mL/min 2 (8.7)
3-5, 60 mL/min 14 (60.9)
Blood cell count
White blood cells, nL1 13.2  5.4
Hemoglobin, g/dL 13.1  5.4
Hematocrit, % 38.6  7.2
Platelets, nL1 234  106
Inflammation markers
CRP, mg/L 9.8  8.7
Fibrinogen, g/L 6.1  2.1
CK, Creatine kinase; CKD, chronic kidney disease; CRP, C-reactive protein
aCategoric data are presented as number (%); continuous data as mean  stmg/dL; P .03) and a lower eGFR (55 33 vs 77 43 tL/min; P  .01; Table II). Furthermore, we observed
igher rates of elevated cTnT and higher rates of mor-
ality or amputation with decreasing eGFR or rather
igher stages of CKD (Fig, A and B). However, nine of
3 patients (39%) who died or underwent amputation
Table I) and 25 of 71 patients (35%) with cTnT values
0.01 ng/mL (Table III) had eGFR values within the
eference range.
Multivariate Cox regression analysis. After adjust-
ent for age, sex, eGFR, CRP, the presence or absence
f known CAD, current smoking, diabetes mellitus,
rterial hypertension, hypercholesterolemia, and the in-
erval between symptom onset and revascularization, the
isk of death or amputation remained increased with
TnT 0.01 ng/mL (HR, 3.4; 95% CI, 1.3-8.5; P 
01) and was even higher with cTnT0.03 ng/mL (HR,
.5; 95% CI, 1.7-11.9; P  .02). Fitting of additional
odels showed that the adjusted HR of death or ampu-
ation associated with an impaired kidney function was
igher among patients with CKD stages 3 to 5 (HR, 3.0;
5% CI, 1.1-8.1; P  .033) compared with patients with
ormal kidney function. The presence of CAD, a higher
RP, and a longer period between symptom onset and
evascularization were identified as additional risk fac-
mb ischemia according to in-hospital outcome (death or
tion Amputation-free survival
(n  231) P
59 (25.5) .013
29 (12.6) .009
284  694 .001
24.0  35.4 .001
204  72 .001
769  2375 .001
838  2320 .001
1.2  1.0 .030
77  43 .013
76 (32.9) . . .
67 (29.0) . . .
68 (29.4) . . .
14 (6.1) . . .
6 (2.6) . . .
88 (38.1) .044
8.9  3.1 .001
13.6  1.9 .100
40.3  5.0 .139
238  92 .683
2.1  3.8 .001
4.7  1.6 .004
R, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
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dependently predictive (Table V).
Elevated cTnT and evidence of myocardial ischemia.
No patient included in this analysis presented with clinical
symptoms indicating an ACS. Patients with an ACS 14
days before ALI had been excluded from the analysis. In
addition, the interpretation of ECGs performed upon ad-
mission to the hospital did not reveal a difference in the
frequency of ECG criteria indicative for acute myocardial
infarction in patients with and without elevated cTnT,
although there was a trend for a higher frequency of ST
depression or T inversion, or both, among patients with
elevated cTnT (Table VI).
DISCUSSION
In the present study, we examined the association be-
tween elevated cTnT on admission to the hospital and in-
hospital outcomes in patients with acute lower limb ischemia.
More important, we assessed the risk of in-hospital death or
amputation in patients without clinical evidence of acute
myocardial ischemia according to the latest version of the
Table III. Patient characteristics according to cardiac trop
Variablea 0.01 ng/mL
Age, years 78 
Male sex 44 (6
Vascular risk factors and comorbidities
Current smoker 9 (1
Diabetes mellitus 35 (4
Arterial hypertension 60 (8
Hypercholesterolemia 42 (5
Coronary artery disease 32 (4
Atrial fibrillation 39 (5
Prior cerebral infarction 12 (1
Prior peripheral vascularization
Endovascular revascularization 30 (4
Bypass surgery 9 (1
Prior amputation 11 (1
PAOD characteristics
Rutherford category
I 18 (2
IIA 13 (1
IIB 40 (5
Ankle-brachial index 0.18 
Time since symptom onset, days 2.5 
Renal function parameters
Creatinine, mg/dL 1.9 
eGFR, mL/min 45 
CKD 3-5 (eGFR 60 mL/min) 46 (6
End-stage renal disease 9 (1
Skeletal muscle enzymes
CK (U/mL) 623 
CK-MB (U/mL) 36 
LDH (U/mL) 265 
CKmax (U/mL) 1672 
Myoglobinmax (ng/mL) 3163 
CK, Creatine kinase; CKD, chronic kidney disease; eGFR, estimated glom
occlusive disease.
aCategoric variables shown as number (%); continuous variables as mean ESC/ACCF redefinition of myocardial infarction consen- rus document.1 The cutoff concentrations used for cTnT
ere0.01 ng/mL (99th percentile in a reference popula-
ion) and 0.03 ng/mL (cutoff for the definition of myo-
ardial necrosis).16 All patients underwent an endovascular
pproach to re-establish arterial blood flow.
Elevated vs normal cTnT, as defined by any of the
utoff concentrations, was associated with an increased risk
f death or amputation in our cohort. Even small elevations
f cTnT to levels that were lower than those used to
iagnose acute myocardial infarctions were associated with
worse in-hospital outcome in patients with ALI, even after
djusting for potential confounders, such as age, sex,
GFR, CRP, the presence or absence of CAD and tradi-
ional vascular risk factors, and the interval between symp-
om onset and revascularization. The cut-off level of0.01
g/mL revealed a 3.4-fold (95% CI, 1.3-8.5) elevated
elative risk of in-hospital death or amputation in patients
ith ALI. However, this result can be mainly attributed to
he higher mortality rate of 11.3% among patients with
levated cTnT, whereas the difference in the amputation
T levels at baseline
Cardiac troponin T
P71) 0.01 ng/mL (n  183)
69  13 0.001
111 (61) .887
55 (30) .004
40 (22) .001
153 (84) .861
133 (73) .049
59 (32) .060
39 (21) .001
13 (7) .032
88 (48) .484
48 (26) .020
9 (5) .008
72 (39) .041
64 (35) .010
47 (26) .001
0.19  0.28 .117
2.9  2.6 .041
0.9  0.3 0.001
85  42 .001
56 (31) .001
0 (0) .001
239  521 .010
21  14 .004
196  59 .001
811  2545 .003
1057  4563 .001
r filtration rate; LDH, lactate dehydrogenase; PAOD, peripheral arterial
rd deviation.onin
(n 
12
2)
3)
9)
5)
9)
5)
6)
7)
2)
3)
6)
5)
8)
6)
0.40
2.6
1.6
30
5)
3)
1150
60
114
3384
4964
erulaates alone was not significant.
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March 2012726 Linnemann et alPlasma cTnT levels in healthy subjects are supposed to
be 0.0001 to 0.0002 ng/mL and are thought to result
from a continuous microscopic loss of cardiomyocytes dur-
ing normal life.18 There is growing evidence to suggest that
an elevation in cardiac troponins indicates an increased risk
of cardiac disease and unfavorable outcomes even in a
healthy population.
According to the results of the population-based Dallas
Heart Study, the prevalence of elevated cTnT (ie, 0.01
ng/mL) measured with a standard assay was as low as 0.7%
in a representative population sample aged 30 to 65 years.19
According to recently published study that used a novel,
highly sensitive assay, the prevalence of detectable cTnT
(ie, 0.003 ng/mL) in the same cohort was even higher
and was reported to be up to 25.0%.20 Elevated cTnT
values were associated with the presence of structural heart
disease and a subsequent risk of all-cause mortality.19,20
Increased risks of CAD, heart failure, and death associated
with detectable cTnT levels in highly sensitive assays were
also described in a post hoc analysis of the ARIC (Athero-
sclerosis Risk in Communities) study and in the Cardiovas-
cular Health Study (CHS) populations.21,22
In a Swedish study of elderly men who had no cardiac
symptoms at the time of blood sampling, those with an
elevated cTnI had an increased risk of death or a first CAD
event.23 Ammann et al24 studied the prognostic value of
cTnI elevations in critically ill patients without evidence of
ACS and found that elevated cTnI levels were an indepen-
dent predictor of 30-day death and decreased left ventric-
ular systolic function. In another study, Pham et al25 inves-
tigated cTnI levels among 366 patients with suspected
myocardial infarction but without definite ACS, including
57 patients with low levels of cTnI (0.01-0.03 ng/mL) and
309 patients with cTnI levels 0.01 ng/mL. Low-level
cTnI elevations were associated with an increased risk of
Table IV. Endovascular revascularization procedures and
outcome according to cardiac troponin T levels
Variables
Cardiac troponin T, No. (%)
P
0.01 ng/mL
(n  71)
0.01 ng/mL
(n  183)
Endovascular
revascularization
Mechanical
thrombectomy 41 (57.7) 114 (62.3) .567
Local thrombolysis 28 (39.4) 107 (58.5) .008
Catheter thrombus
aspiration
22 (31.0) 59 (32.2) .882
Angioplasty/stenting 52 (73.0) 141 (77.0) .517
Mechanical
atherectomy
1 (1.4) 4 (2.2) .99
In-hospital outcome
Death or
amputation
12 (16.9) 11 (6.0) .013
Death 8 (11.3) 2 (1.1) .001
Amputation 4 (5.6) 9 (4.9) .760future cardiovascular events during the 1-year follow-up.25 oElevated concentrations of cTns are often observed in
atients with advanced CKD but without clinical signs of
yocardial ischemia. In a large study that included 733
symptomatic patients with end-stage renal disease, a high
ercentage of the patients had elevated concentrations of
roponins.15 The authors reported elevated cTnT preva-
ences of 82% with a 0.01 ng/mL cutoff and 53% with a
.03 ng/mL cutoff. In our study, elevated cTnT was
revalent in 28.0% and 14.6% of patients, respectively,
hen the 0.01 and 0.03 ng/mL cutoffs were applied. We
lso observed higher frequencies of elevated cTnT with
eclining renal function. Therefore, it is plausible that the
ssociation between cTnT levels and adverse in-hospital
utcomes was at least partly due to impaired renal function,
hich by itself is indicative of an adverse outcome. How-
ver, our data reveal that cTnT levels 0.01 ng/mL re-
ained an independent predictor of death and amputation,
ven after adjusting for eGFR, age, sex, the presence or
bsence of CAD and traditional vascular risk factors, and
he interval between symptom onset and revascularization.
Regarding the baseline characteristics, no disturbance
f renal function was present in 9 of 23 patients (39%) who
ied or underwent amputation and 25 of 71 patients (35%)
ho presented with an elevated cTnT. CAD was unknown
n 32 of 71 (45%; Table I), and the ECG was normal in 43
f 71 patients (61%), despite cTnT values 0.01 ng/mL
n admission to the hospital. Remarkably, no patient suf-
ered a fatal myocardial infarction, but 21 of the 23 patients
91%) with adverse in-hospital outcomes were classified as
aving level IIB ALI according to the Rutherford classifi-
ation and a lower ankle-brachial index on admission,
hich indicates a more severe limb ischemia.
Only recently were cTns identified as a possible risk
tratification tool in patients with chronic critical limb
schemia (CCLI). Sarveswaran et al11 followed up 152
atients with CCLI and without evidence of unstable CAD
nd found that elevated cTnI levels independently pre-
icted mortality during a 2-year period (HR, 4.2; 95% CI,
.3-12.7). In another investigation, Rittoo et al10 found a
igh prevalence of elevated cTnT among 39 patients (44%)
ith ALI.10 Cumulative survival rates after 7 days were 53%
or cTnT-positive patients and 100% for cTnT-negative
atients. In contrast to our study results, no association was
ound between the presence of CAD or higher CRP values
nd death. However, the number of patients included in
his study was small.
Landesberg et al26 and Kertai et al27 previously dem-
nstrated that even low levels of asymptomatic troponin
levation during the perioperative period are associated
ith a poorer long-term outcome in patients undergoing
ajor vascular surgery.26,27 The causes of cTnT elevation
n patients without clinical symptoms of acute myocardial
schemia are not completely understood. First, given the
ssociation between CAD and PAOD, it is very likely that
atients with elevated troponins had more severe coronary
eart disease. Subclinical myocardial damage may result
rom transient or less severe ischemia and as a consequence
f the exposure of myocardial cells to cytokines. In these
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Volume 55, Number 3 Linnemann et al 727situations, troponin molecules may leak through reversibly
permeabilized plasma membranes into the circulation.28
Elevation of cardiac troponins has been described for pa-
tients with microvascular CAD, which frequently occurs in
conjunction with chronic heart failure, diabetes mellitus,
and CKD.23
In the special situation of ALI, the increase in cardiac
troponins seems to be directly associated with rhabdomy-
olysis. The release of necrotic muscle constituents into the
circulationmay have direct toxic effects onmyocardial cells.
With the onset of skeletal muscle ischemia, there is a
conversion of muscle metabolism from aerobic to anaero-
bic that results in an increased production of lactate and the
development of acidosis. Potassium, phosphate, CK, and
myoglobin are released into the systemic circulation. Cyto-
kine liberation, leukocyte activation, prothrombotic eico-
sanoid production, activation of the compartment cascade,
and formation of toxic oxygen metabolites are conse-
Fig. A, Prevalence of elevated cardiac troponin T (cTnT
acute limb ischemia patients according to the chronic k
rate: I,90mL/min; II, 60 to 89mL/min; III, 30 to 59
Table V. Univariate and adjusted hazard ratios (HR) for
worse in-hospital outcomes
Variable
Univariate Adjusted
HR (95% CI) P HR (95% CI)a P
Cardiac troponin T
0.01 ng/mL 3.1 (1.3-7.2) .009 3.4 (1.3-8.5) .010
0.03 ng/mL 3.6 (1.5-8.7) .004 4.5 (1.7-11.9) .020
CKD stages III–V 2.4 (0.9-5.7) .058 3.0 (1.1-8.1) .033
CAD 2.8 (1.1-7.2) .040 4.3 (1.3-14.6) .019
CRP 0.5 mg/L 6.6 (1.5-28.2) .011 5.3 (1.2-23.2) .026
CAD, Coronary artery disease; CI, confidence interval; CKD, chronic
kidney disease; CRP, C-reactive protein.
aAdjusted for age, sex, estimate glomerular filtration rate, CRP, the presence
or absence of known CAD, current smoking, diabetes mellitus, arterial
hypertension, hypercholesterolemia, and the interval between symptom
onset and revascularization.quences of these changes that lead to the clinical manifes- wation of SIRS.10,29,30 SIRS may contribute to cardiac and
enal dysfunction and lead to multiorgan failure. Remark-
bly, the cause of death for 8 of 10 patients in our cohort
as progressive ischemia, septicemia, and multiorgan fail-
re. The aforementioned mechanisms are further amplified
y reperfusion.
ALI is one of themost frequent reasons for amputation.
wo primary factors explain the high morbidity and mor-
ality that result from ALI: the underlying comorbidities
nd the delay in the recognition and treatment of ischemia.
ven with the extensive use of newer endovascular tech-
iques, amputation rates of 10% to 25% are reported, and
ortality is approximately 10%.14,31 Older age, a lower
ody weight, significant underlying atherosclerosis, and the
resence of diabetes mellitus, chronic heart failure, CKD,
nd malignancy have been previously identified as predic-
ors of poorer in-hospital outcomes.31 The results of the
urgery vs. Thrombolysis for Ischemia of the Lower Ex-
remity (STILE) and Thrombolysis or Peripheral Arterial
urgery (TOPAS) studies suggest the equivalence of endo-
ascular or surgical therapies, as measured by death or
mputation.32,33
At our institution, a primary endovascular approach
ombining different techniques, such as mechanical throm-
ectomy, catheter thrombus aspiration, local thrombolysis,
ercutaneous transluminal angioplasty and stent place-
ent, and atherectomy, was chosen to re-establish blood
ow to the ischemic lower limb. The rates of in-hospital
ortality and amputation in our cohort were unexpectedly
ow (3.8% and 5.1%, respectively). These favorable results
ay be explained by the combination of different tech-
iques for revascularization depending on the anatomic
ocation and the short duration between the onset of symp-
oms and the revascularization procedure.
Our study has some important limitations. First, this is
retrospective study design. Because patients presented
01 ng/mL) and (B) in-hospital death or amputation in
disease classification by estimated glomerular filtration
min; IV, 15 to 29mL/min; V,15mL/min or dialysis.0.
idneyith ALI that required a rapid revascularization strategy in
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March 2012728 Linnemann et almost cases but had no clinical symptoms of myocardial
ischemia, we lack serial troponin measurements. Therefore,
we cannot distinguish accurately between elevations due to
acute silent myocardial ischemia and chronic disease, which
is a major limitation to the interpretation of our results.
According to the consensus statement of the ESC/ACCF/
AHA/WHF Task Force, a rise and/or fall in cardiac bio-
markers, in addition to clinical symptoms of ischemia or
typical ECG changes, is required for the diagnosis of myo-
cardial infarction.1 However, patients with unfavorable
outcomes presented more frequently with ST segment
depression or T inversion that were possibly indicative of
silent myocardial ischemia, even though this difference was
not significant. Because we only examined the ECG per-
formed at hospital admission, we are not certain whether
the ECG changes were really “new,” as required for the
diagnosis of acute myocardial ischemia.
Second, there is evidence that patients with elevated
troponins in our cohort had higher rates of diabetes melli-
tus, chronic renal failure, CAD, and prior cerebral infarc-
tion. Therefore, it can be supposed that those patients who
had more serious comorbidities underwent more cautious
or less ideal revascularization procedures. Indeed, we ob-
served that local thrombolysis was performed less fre-
quently among patients with elevated cTnT, which might
be attributed to the potentially higher bleeding risk. How-
ever, there was no difference between the other revascular-
ization procedures performed in patients with and without
elevated cTnT.
Finally, overall rates for mortality and amputations in
our study were low, thereby explaining the low number of
patients with poorer in-hospital outcomes.
CONCLUSIONS
Among patients with ALI and without clinical symp-
toms suggesting myocardial ischemia, elevated cTnT levels
at the time of hospital admission can identify patients at risk
of in-hospital death or amputation. Even small elevations of
cTnT (0.01 ng/mL) predict a markedly increased risk of
poorer in-hospital outcomes. In addition to serial cTnT
measurements and ECG recordings to rule out silent myo-
cardial ischemia, these patients deserve intensive care and
monitoring of cardiac function after immediate endovascu-
Table VI. Prevalence of electrocardiograph criteria indicat
without elevated cardiac troponin Ta
Variable
Cardiac troponin T
0.01 ng/mL
(n  71)
0.01
(n 
ST elevation 3.4
ST depression and/or T inversion 31.4 2
Left bundle branch block 4.2
aAccording to the consensus document of the Joint European Society of Car
Heart Association (AHA)/World Heart Federation (WHF) Task Force forlar revascularization for ALI.UTHOR CONTRIBUTIONS
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